
export type InsightCategory = 'Strategic Intelligence' | 'Execution Protocol' | 'Institutional Case Study';

export interface Insight {
    id: string;
    title: string;
    slug: string;
    category: InsightCategory;
    date: string;
    excerpt: string;
    readTime: string;
    coverImage: string;
    content: string;
    author: {
        name: string;
        role: string;
    };
}

export const insights: Insight[] = [
    {
        id: '1',
        title: 'Recursive AI in Expert Matching: A New Standard for Diligence',
        slug: 'recursive-ai-expert-matching',
        category: 'Execution Protocol',
        date: 'February 24, 2026',
        excerpt: 'How proprietary algorithms are replacing manual database searches to identify granular industry expertise in under 2 hours.',
        readTime: '6 min read',
        coverImage: '/insights/matching.webp',
        content: `
            <p>In the high-stakes world of private equity and strategic consulting, the speed of insight is often the difference between a winning bid and a secondary position. Traditional expert networks rely on static databases and manual recruiters—a process that is increasingly out of step with the velocity of modern markets.</p>
            
            <h3>The Shift to Recursive AI</h3>
            <p>At SignalBridge, we have pioneered a "Recursive AI" approach to expert identification. Unlike basic keyword searches, our system analyzes the specific research thesis of a project and recursively maps the knowledge requirements against real-time industry shifts.</p>
            
            <h3>Why 24 Hours is No Longer Fast Enough</h3>
            <p>Our methodology ensures that within 120 minutes of a briefcase submission, we have not just a list of names, but a ranked hierarchy of specialists who have operated in the niche sub-sectors our clients require.</p>
            
            <h3>Compliance by Design</h3>
            <p>By integrating compliance screening directly into the AI workflow, we eliminate the friction of manual NDAs and MNPI avoidance protocols, allowing for rapid execution without regulatory risk.</p>
        `,
        author: {
            name: 'Robert Vance',
            role: 'Head of Research Architecture'
        }
    },
    {
        id: '2',
        title: 'The TMT Landscape in 2026: Consolidation and Convergence',
        slug: 'tmt-landscape-2026',
        category: 'Strategic Intelligence',
        date: 'February 18, 2026',
        excerpt: 'An analysis of why expert-led primary research is seeing a 40% uptick in the telecommunications and nascent AI sub-sectors.',
        readTime: '8 min read',
        coverImage: '/insights/tmt.webp',
        content: `
            <p>As we move further into 2026, the Technology, Media, and Telecommunications (TMT) sector is entering a phase of hyper-speed consolidation. The convergence of edge computing and specialized AI models has created a knowledge vacuum that traditional secondary research cannot fill.</p>
            
            <h3>Primary Research as a Competitive Edge</h3>
            <p>Our data shows a marked shift in investor behavior. 40% more institutional clients are bypassing standard analyst reports in favor of direct expert surveys. The goal? To understand the supply chain friction points that are not yet visible in public filings.</p>
            
            <h3>The Signal of Convergence</h3>
            <p>When media giants begin acquiring hardware infrastructure providers, the "Expert Call" becomes an essential tool for understanding cultural integration and technical compatibility—the two primary killers of TMT deals.</p>
        `,
        author: {
            name: 'Sarah Chen, PhD',
            role: 'Principal Strategist'
        }
    },
    {
        id: '3',
        title: 'Case Study: Accelerating a $4B Sovereign Wealth Fund Entry',
        slug: 'case-study-sovereign-wealth-entry',
        category: 'Institutional Case Study',
        date: 'January 12, 2026',
        excerpt: 'How SignalBridge provided 40+ vetted experts in 48 hours to support a rapid market entry strategy in Southeast Asia.',
        readTime: '10 min read',
        coverImage: '/insights/case-study.webp',
        content: `
            <p>A major Sovereign Wealth Fund required deep-dive expertise into the renewable energy infrastructure of Singapore and Vietnam. The catch? The research phase was restricted to a 72-hour window before the final investment committee meeting.</p>
            
            <h3>The Challenge</h3>
            <p>Identifying localized operational expertise across two distinct regulatory environments within a weekend. Traditional networks estimated a 5-7 day lead time.</p>
            
            <h3>The SignalBridge Execution</h3>
            <p>Using our global network and protocol-driven screening, we initialized a "Strategic Desk" dedicated to the project. Within 48 hours, the client had completed 42 consultations with former utility heads and regulatory officials.</p>
            
            <h3>The Result</h3>
            <p>The fund proceeded with the $4B market entry, citing the granular local data obtained through SignalBridge as the deciding factor in their valuation model.</p>
        `,
        author: {
            name: 'Marcus Thorne',
            role: 'Director of Institutional Partnerships'
        }
    },
    {
        id: '4',
        title: 'Life Sciences 2026: Navigating the FDAs Accelerated Digital Pivot',
        slug: 'healthcare-fd-digital-pivot',
        category: 'Strategic Intelligence',
        date: 'January 05, 2026',
        excerpt: 'How primary research is helping Biotech VCs demystify the new regulatory frameworks for AI-driven drug discovery.',
        readTime: '7 min read',
        coverImage: '/insights/healthcare.webp',
        content: `
            <p>The life sciences sector is currently undergoing its most significant regulatory shift in a decade. The FDA's new "Digital Pivot" framework for AI-led clinical trials has created a high-stakes environment for investors who are used to traditional drug development timelines.</p>
            
            <h3>The Knowledge Gap in AI-Discovery</h3>
            <p>Our recent survey of 50+ former FDA officials and Chief Medical Officers reveals that while AI can cut R&D time by 30%, the regulatory "black box" remains the primary hurdle for valuation. Institutional investors are increasingly seeking experts who have sat on the review boards of the first AI-cleared drugs.</p>
            
            <h3>Precision Matching for Healthcare VC</h3>
            <p>SignalBridge has seen a 60% increase in requests for bioinformatics specialists and regulatory consultants who can translate complex technical filings into high-fidelity investment signals.</p>
        `,
        author: {
            name: 'Dr. Elena Rossi',
            role: 'Senior Advisor, Life Sciences'
        }
    },
    {
        id: '5',
        title: 'Institutional ESG 2.0: Deep-Dive Due Diligence vs. Greenwashing',
        slug: 'institutional-esg-compliance',
        category: 'Execution Protocol',
        date: 'December 20, 2025',
        excerpt: 'Why checking the box is no longer enough. How expert insights are revealing the operational reality of corporate sustainability claims.',
        readTime: '9 min read',
        coverImage: '/insights/esg.webp',
        content: `
            <p>The era of "Check-the-box" ESG is over. SEC and EU regulators are now targeting the "operational mismatch" between corporate sustainability reports and the reality of on-the-ground supply chain operations.</p>
            
            <h3>The Operational Audit</h3>
            <p>SignalBridge provides a "Compliance Shield" for ESG investments by connecting analysts with former supply chain heads and environmental auditors. These experts provide the qualitative data that standard ESG ratings often miss.</p>
            
            <h3>Protocol 7: The New Standard</h3>
            <p>Our Protocol 7 compliance framework ensures that all ESG-related expert interactions are audited, secure, and focused on verifiable operational data, protecting our clients from the rising tide of greenwashing litigation.</p>
        `,
        author: {
            name: 'Jonathan Sterling',
            role: 'Head of Global Compliance'
        }
    },
    {
        id: '6',
        title: 'Precision Therapeutics: The 2026 Pharma-Biotech Convergence',
        slug: 'precision-therapeutics-biotech-pharma',
        category: 'Strategic Intelligence',
        date: 'December 05, 2025',
        excerpt: 'How expert-led insights are accelerating the transition from blockbuster drugs to scalable genomic therapeutics.',
        readTime: '11 min read',
        coverImage: '/insights/pharma.webp',
        content: `
            <p>The pharmaceutical industry is moving away from the "one-size-fits-all" blockbuster model toward precision therapeutics. This shift is being driven by a rapid convergence between agile biotech firms and traditional pharma giants seeking to refresh their pipelines.</p>
            
            <h3>The Therapeutics Scalability Crisis</h3>
            <p>While the science behind personalized medicine is proven, the scalability remains an operational nightmare. Investors are now prioritizing expert consultations with former heads of manufacturing and cold-chain logistics who have managed the rollout of mRNA and cell therapies.</p>
            
            <h3>Why Primary Research is Key in Biotech</h3>
            <p>In the biotech space, a single clinical trial result can swing a valuation by billions. SignalBridge connects institutional analysts with the scientists and medical directors who can provide the qualitative context behind the quantitative data, focusing on the nuances of therapeutic efficacy and commercial viability.</p>
            
            <h3>The Future of Genomic Medicine</h3>
            <p>As we look toward 2027, the "Signal" is clear: success in therapeutics will depend on the ability to integrate deep scientific expertise with mid-market operational reality.</p>
        `,
        author: {
            name: 'Dr. Alistair Vaughn',
            role: 'Lead Strategist, Therapeutics & Pharma'
        }
    }
];
